Home Cart Sign in  
Chemical Structure| 473727-83-2 Chemical Structure| 473727-83-2

Structure of Navarixin
CAS No.: 473727-83-2

Chemical Structure| 473727-83-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SCH-527123 is a potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively.

Synonyms: SCH 527123; MK-7123; Navarixin monohydrate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Navarixin

CAS No. :473727-83-2
Formula : C21H23N3O5
M.W : 397.42
SMILES Code : O=C(N(C)C)C1=CC=CC(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)=C1O
Synonyms :
SCH 527123; MK-7123; Navarixin monohydrate
MDL No. :MFCD16628072
InChI Key :RXIUEIPPLAFSDF-CYBMUJFWSA-N
Pubchem ID :9865554

Safety of Navarixin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Navarixin

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PC-3 cells 5 µM 24 hours Navarixin inhibited the invasive ability of PC-3 cells. PMC9970838
Microglial cells  128.05 µM and 23.78 µM Navarixin inhibited CCL21-induced microglial migration and proliferation. PMC11789347
S635 cells 25 µM 7 days Evaluate the effect of Navarixin on S635 cell migration, results showed no significant effect of Navarixin alone on cell migration PMC10706712
LNCaP cells 5 µM 24 hours Navarixin suppressed IL-8-induced increases in IL-8, CXCR2, MMP-2/9, Snail, and vimentin expression and restored AR and E-cadherin expression. PMC9970838

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice DOPAL or αSynO-induced Parkinson's disease model Intraventricular injection 3 µg/mouse Single injection, 30 minutes before DOPAL or αSynO treatment To evaluate the protective effect of Navarixin in PD model mice, results showed Navarixin pretreatment prevented DOPAL or αSynO-induced motor and non-motor deficits PMC11789347
C57BL/6 male mice Myocardial infarction model Oral 1 mg/kg Once daily for 4 weeks Nav improved cardiac function, reduced myocardial damage, reduced neutrophil infiltration, reduced inflammatory factor expression and improved cardiac fibrosis in mice. PMC11966465

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03473925 Solid Tumors ... More >>Non-small Cell Lung Cancer Castration Resistant Prostate Cancer Microsatellite Stable Colorectal Cancer Less << Phase 2 Recruiting August 9, 2019 United States, Arizona ... More >> Honor Health ( Site 0005) Recruiting Scottsdale, Arizona, United States, 85258 Contact: Study Coordinator    623-238-7685       United States, Florida Florida Cancer Specialists ( Site 0003) Recruiting Sarasota, Florida, United States, 34232 Contact: Study Coordinator    941-377-9993       United States, Michigan Henry Ford Health System ( Site 0006) Recruiting Detroit, Michigan, United States, 48202 Contact: Study Coordinator    313-916-1784       United States, North Carolina Duke University Medical Center ( Site 0004) Recruiting Durham, North Carolina, United States, 27710 Contact: Study Coordinator    919-668-8797       Australia, New South Wales Scientia Clinical Research ( Site 0021) Recruiting Sydney, New South Wales, Australia, 2031 Contact: Study Coordinator    +61293825807       Australia, Victoria Peter MacCallum Cancer Centre ( Site 0023) Recruiting Melbourne, Victoria, Australia, 3000 Contact: Study Coordinator    +61385595000       Canada, Ontario Princess Margaret Cancer Centre ( Site 0031) Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Study Coordinator    41694645015634       Canada, Quebec Jewish General Hospital ( Site 0032) Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Study Coordinator    5143408222       Israel Sourasky Medical Center ( Site 0012) Recruiting Tel Aviv, Israel, 6423906 Contact: Study Coordinator    +97236973082       Korea, Republic of Severance Hospital Yonsei University Health System ( Site 0041) Recruiting Seoul, Korea, Republic of, 03722 Contact: Study Coordinator    +82222288132 Less <<
NCT00632502 Neutrophilic Asthma Phase 2 Completed - -
NCT00684593 Psoriasis Phase 2 Completed - -
NCT00632502 - Completed - -
NCT01006616 COPD Phase 2 Terminated - -
NCT00684593 - Completed - -
NCT00441701 - Terminated - -
NCT00688467 Asthma Phase 2 Completed - -
NCT00441701 Chronic Obstructive Pulmonary ... More >>Disease Less << Phase 2 Terminated - -
NCT01006161 Asthma Phase 2 Withdrawn August 2012 -
NCT01068145 Chronic Obstructive Pulmonary ... More >>Disease Less << Phase 1 Terminated - -
NCT01006616 - Terminated - -
NCT00688467 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.58mL

2.52mL

1.26mL

25.16mL

5.03mL

2.52mL

References

 

Historical Records

Categories